The Toronto-based firm is rolling out the technology at the Flow Water facility in Ontario and at a 24-hour pharmacy in Montreal, it said.
Predictmedix has proprietary artificial intelligence technology to screen for infectious diseases such as influenza and coronaviruses, recently developing a predictive mass screening tool for COVID-19. The technology is used to predict and identify individuals who have the highest likelihood of being infected with the virus.
READ: Predictmedix executes sales contract for its COVID-19 screening technology with North American brand-builder Juiceworks Exhibits
The deployment at Flow Water’s Aurora facility comes as part of Predictmedix’s contract with North American exhibit marketing firm Juiceworks Exhibits, which is offering safe indoor and outdoor entry solutions using custom-fabricated temporary structures that utilize the company’s COVID-19 mass screening technology. All of the entry solutions being sold by Juiceworks across North America will be retrofitted with Predictmedix technology for COVID-19 mass screening.
Nick Reichenbach, Flow Water’s CEO, told investors that the effects of even a single case of coronavirus at its production facility could have a significant impact on its operations as well as the health and safety of its staff.
“Having Safe Entry's technology here may provide an extra layer of safety for the Flow family and ultimately our communities, and we're glad to be able to pilot this technology here in our flagship facility,” Reichenbach said in a statement.
In Montreal, Predictmedix is rolling out its technology at the city’s only 24-hour pharmacy, positioning it within a new vertical, according to COO Rahul Kushwah.
“Ensuring continuous function of pharmacies during the COVID-19 pandemic is important,” Kushwah said in the same statement. “(There) is a need to implement technologies which can create a safer environment in pharmacies for the employees, customers, and patients.”
The technology deployment is scheduled within the next few weeks.
Contact Angela at [email protected]
Follow her on Twitter @AHarmantas